Original title: biochip and Changchun hi tech terminate cooperation with COVID-19 on vaccine
The Beijing News (reporter Liu Xu) on September 27th, the Changchun biotech company and its parent company, new high tech, announced the termination of the licensing cooperation related transaction with the New Coronavirus PIV-5 biotech Co., Ltd. (New Coronavirus).
In June 2021, the Changchun biotech company and its parent company, PIV-5, signed the license cooperation agreement with the PIV-5, a new coronal 2 virus vaccine (PIV-5), and the exclusive licensing rights of related technologies in the licensed area, as well as the exclusive production rights in other Asian regions outside the licensing area and in the Oceania region. 。
Up to now, the above license cooperation agreement has not been signed. Changchun high tech and 100 grams of organisms have not actually invested in the development of New Coronavirus vaccine (PIV-5 carrier), and the biological research and evaluation of the project cost 1 million 553 thousand and 500 yuan.
In order to ensure the smooth development of New Coronavirus vaccine (PIV-5 carrier), Changchun high tech and 100 grams of biotech are trying to verify the feasibility of the New Coronavirus vaccine (PIV-5 carrier) to deal with the variation of the strain, and verify the formal agreement after verification, Bai Ke said. Si'anxin does not agree to hand over biological materials for confirmatory experiments without signing a formal agreement; In view of the fact that phase I clinical trials of the vaccine have been carried out in the United States, Si Anxin requires to improve the project valuation. Since the parties could not reach an agreement on the above contents, they agreed to terminate the formal signing of the license cooperation agreement and subsequent cooperation.
Proofread by Liu Baoqing